GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals Inc (NAS:SCLN) » Definitions » Graham Number

SciClone Pharmaceuticals (SciClone Pharmaceuticals) Graham Number : $8.78 (As of Jun. 2017)


View and export this data going back to 1992. Start your Free Trial

What is SciClone Pharmaceuticals Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-04-26), the stock price of SciClone Pharmaceuticals is $11.15. SciClone Pharmaceuticals's graham number for the quarter that ended in Jun. 2017 was $8.78. Therefore, SciClone Pharmaceuticals's Price to Graham Number ratio for today is 1.27.

The historical rank and industry rank for SciClone Pharmaceuticals's Graham Number or its related term are showing as below:

SCLN's Price-to-Graham-Number is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


SciClone Pharmaceuticals Graham Number Historical Data

The historical data trend for SciClone Pharmaceuticals's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals Graham Number Chart

SciClone Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.68 3.09 5.11 6.11 6.86

SciClone Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.32 7.39 6.86 7.91 8.78

Competitive Comparison of SciClone Pharmaceuticals's Graham Number

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals's Price-to-Graham-Number Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals's Price-to-Graham-Number falls into.



SciClone Pharmaceuticals Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

SciClone Pharmaceuticals's Graham Number for the fiscal year that ended in Dec. 2016 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*3.601*0.58)
=6.86

SciClone Pharmaceuticals's Graham Number for the quarter that ended in Jun. 2017 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*4.182*0.82)
=8.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SciClone Pharmaceuticals  (NAS:SCLN) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

SciClone Pharmaceuticals's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Jun. 2017 )
=11.15/8.78
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


SciClone Pharmaceuticals Graham Number Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (SciClone Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.
Executives
Richard J Hawkins director 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Nancy T Chang director 101 WESTCOTT, SUITE 603, HOUSTON TX 77007
Raymond Anthony Low director, officer: VP, Finance & Controller 25 SHADOW TREE CT, DANVILLE CA 94506
Wilson Wai-shun Cheung officer: CFO & Senior VP, Finance SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Robert King officer: SVP of Prod. Dev/Supply Chain 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Winnie Wing-kei Tso other: VP, Finance and Controller 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Stephanie Wong officer: VP, Finance and Controller 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Gary Titus officer: Senior VP Finance & CFO SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Farmaceutica Lda Defiante 10 percent owner RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082
Dean S Woodman director 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480